481 related articles for article (PubMed ID: 34722271)
1. Metabolomics Profiling Discriminates Prostate Cancer From Benign Prostatic Hyperplasia Within the Prostate-Specific Antigen Gray Zone.
Xu B; Chen Y; Chen X; Gan L; Zhang Y; Feng J; Yu L
Front Oncol; 2021; 11():730638. PubMed ID: 34722271
[TBL] [Abstract][Full Text] [Related]
2. Serum Metabolic Profiling Analysis of Chronic Gastritis and Gastric Cancer by Untargeted Metabolomics.
Yu L; Lai Q; Feng Q; Li Y; Feng J; Xu B
Front Oncol; 2021; 11():636917. PubMed ID: 33777793
[TBL] [Abstract][Full Text] [Related]
3. Identification of the metabolic signatures of prostate cancer by mass spectrometry-based plasma and urine metabolomics analysis.
Yu C; Niu L; Li L; Li T; Duan L; He Z; Zhao Y; Zou L; Wu X; Luo C
Prostate; 2021 Dec; 81(16):1320-1328. PubMed ID: 34590739
[TBL] [Abstract][Full Text] [Related]
4. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
5. Serum organic acid metabolites can be used as potential biomarkers to identify prostatitis, benign prostatic hyperplasia, and prostate cancer.
He J; Han Z; Luo W; Shen J; Xie F; Liao L; Zou G; Luo X; Guo Z; Li Y; Li J; Chen H
Front Immunol; 2022; 13():998447. PubMed ID: 36685547
[TBL] [Abstract][Full Text] [Related]
6. Oxidised low-density lipoprotein, a possible distinguishing lipid profile biomolecule between prostate cancer and benign prostatic hyperplasia.
Asare GA; Owusu-Boateng E; Asiedu B; Amoah BY; Essendoh E; Otoo RY
Andrologia; 2019 Sep; 51(8):e13321. PubMed ID: 31145504
[TBL] [Abstract][Full Text] [Related]
7. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
[TBL] [Abstract][Full Text] [Related]
8. GC-MS-based metabolomics reveals new biomarkers to assist the differentiation of prostate cancer and benign prostatic hyperplasia.
Wang W; He Z; Kong Y; Liu Z; Gong L
Clin Chim Acta; 2021 Aug; 519():10-17. PubMed ID: 33831421
[TBL] [Abstract][Full Text] [Related]
9. [Screening of serum oxysterol biomarkers for colon cancer by liquid chromatography-tandem mass spectrometry].
Ma Z; Li Z; Wang H; Wang R; Han X
Se Pu; 2022 Jun; 40(6):541-546. PubMed ID: 35616199
[TBL] [Abstract][Full Text] [Related]
10. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
11. Lipid metabolism analysis for peripheral blood in patients with alcohol
Yan Y; Yu Y; Liu J; Zhao H; Wang J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Jul; 47(7):872-880. PubMed ID: 36039583
[TBL] [Abstract][Full Text] [Related]
12. Triglyceride to high-density lipoprotein cholesterol ratio and total cholesterol to high-density lipoprotein cholesterol ratio and risk of benign prostatic hyperplasia in Chinese male subjects.
Zhu C; Wu J; Wu Y; Guo W; Lu J; Zhu W; Li X; Xu N; Zhang Q
Front Nutr; 2022; 9():999995. PubMed ID: 36263299
[TBL] [Abstract][Full Text] [Related]
13. Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone.
Kang HW; Byun YJ; Moon SM; Kim K; Piao XM; Zheng CM; Moon SK; Choi YH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
Investig Clin Urol; 2022 Mar; 63(2):238-244. PubMed ID: 35244999
[TBL] [Abstract][Full Text] [Related]
14. Identification of characteristic metabolic panels for different stages of prostate cancer by
Zhang X; Xia B; Zheng H; Ning J; Zhu Y; Shao X; Liu B; Dong B; Gao H
J Transl Med; 2022 Jun; 20(1):275. PubMed ID: 35715864
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models.
Chen M; Ma T; Li J; Zhang HJ; Li Q; Wang JJ; Sang T; Cao CL; Cui XW
Med Sci Monit; 2021 Feb; 27():e929913. PubMed ID: 33556045
[TBL] [Abstract][Full Text] [Related]
16. Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia.
Pérez-Rambla C; Puchades-Carrasco L; García-Flores M; Rubio-Briones J; López-Guerrero JA; Pineda-Lucena A
Metabolomics; 2017; 13(5):52. PubMed ID: 28804274
[TBL] [Abstract][Full Text] [Related]
17. Plasma metabolomic profile in prostatic intraepithelial neoplasia and prostate cancer and associations with the prostate-specific antigen and the Gleason score.
Markin PA; Brito A; Moskaleva N; Lartsova EV; Shpot YV; Lerner YV; Mikhajlov VY; Potoldykova NV; Enikeev DV; La Frano MR; Appolonova SA
Metabolomics; 2020 Jun; 16(7):74. PubMed ID: 32556743
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of lipids, total antioxidants, and trace metals in benign prostate hyperplasia and prostate cancer.
Adedapo KS; Arinola OG; Shittu OB; Kareem OI; Okolo CA; Nwobi LN
Niger J Clin Pract; 2012; 15(3):293-7. PubMed ID: 22960963
[TBL] [Abstract][Full Text] [Related]
19. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
[TBL] [Abstract][Full Text] [Related]
20. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
